Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance

Haematologica

Volumn 99, Issue 3, 2014, Pages 511-518

  Kubiczkova, Lenka ^a,b   Kryukov, Fedor ^a   Slaby, Ondrej ^c   Dementyeva, Elena ^a   Jarkovsky, Jiri ^a   Nekvindova, Jana ^d   Radova, Lenka ^d   Greslikova, Henrieta ^a   Kuglik, Petr ^a   Vetesnikova, Eva ^b   Pour, Ludek ^b   Adam, Zdenek ^b   Sevcikova, Sabina ^a,b   Hajek, Roman ^a,b,e  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

^e UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE; HEMOGLOBIN; LACTATE DEHYDROGENASE; MICRORNA; MICRORNA 103; MICRORNA 10B; MICRORNA 1243; MICRORNA 1274A; MICRORNA 130A; MICRORNA 138; MICRORNA 151 5P; MICRORNA 191; MICRORNA 218; MICRORNA 222; MICRORNA 34A; MICRORNA 744; MICRORNA LET 7D; MICRORNA LET 7E; PARAPROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER REGRESSION; CHEMICAL ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DOWN REGULATION; EXOSOME; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TAQMAN LOW DENSITY ARRAY; THROMBOCYTE COUNT; UPREGULATION; BLOOD; CANCER STAGING; CASE CONTROL STUDY; CHROMOSOME ABERRATION; CLUSTER ANALYSIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; PROGNOSIS; REPRODUCIBILITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84895725205     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.093500     Document Type: Article

References (43)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962-72.
2. Hájek R, Krejcí M, Pour L, Adam Z. Multiple myeloma. Klin Onkol. 2011;24 Suppl:S10-3.
3. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol. 2007;139(5):730-43.
4. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008;22(10):1933-7.
5. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812-7.
6. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009;7(9):908-42.
7. Jones CI, Zabolotskaya MV, King AJ, Stewart HJ, Horne GA, Chevassut TJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 2012;107(12):1987-96.
8. Yyusnita, Norsiah, Zakiah I, Chang KM, Purushotaman VS, Zubaidah Z, et al. MicroRNA (miRNA) expression profiling of peripheral blood samples in multiple myeloma patients using microarray. Malays J Pathol. 2012;34(2):133-43.
9. Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma. 2013;54(1):189-91.
10. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev. 2004;18(5):504-11.
11. Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA. 2006;103(11):4034-9.
12. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-69.
13. Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E, et al. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets. 2012;16 Suppl 2: S103-9.
14. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105(35):12885-90.
15. Lionetti M Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009;114(25):e20-6.
16. Corthals SL, Sun SM, Kuiper R, de Knegt Y, Broyl A, van der Holt B, et al. MicroRNA signatures characterize multiple myeloma patients. Leukemia. 2011;25(11):1784-9.
17. Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 2010;24(3):629-37.
18. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012;18(22):6260-70.
19. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2011;80(2):193-208.
20. Chen X, Liang H, Zhang J, Zen K, Zhang CY. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012;22(3):125-32.
21. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223-33.
22. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS One. 2008;3(9):e3148.
23. Buresova I, Cumova J, Kovarova L, Stossova J, Dementyeva E, Kryukov F, et al. Bone marrow plasma cell separation-validation of separation algorithm. Clin Chem Lab Med. 2012;50(6):1139-40.
24. Zhang C, Wang C, Chen X, Yang C, Li K, Wang J, et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem. 2010;56(12):1871-9.
25. Nemec P, Zemanova Z, Kuglik P, Michalova K, Tajtlova J, Kaisarova P, et al. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma. 2012;53(5):920-7.
26. Reimers M, Carey VJ. Bioconductor: an open source framework for bioinformatics and computational biology. Methods Enzymol. 2006;411:119-34.
27. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013. Available from: URL http://www.R-project.org/.
28. Smyth, GK. Limma: linear models for microarray data. In:'Bioinformatics and Computational Biology Solutions using R and Bioconductor'. Gentleman R, Carey V, S. Dudoit S, Irizarry R, Huber W (eds), Springer. New York. 2005. p. 397-420.
29. Rocci A, Hofmeister C, Omede P, Geyer S, Bringhen S, Cascione L, et al. Circulating microRNA in multiple myeloma: Differences in healthy subjects and correlation with biological parameters. 17th Congress of the European Hematology Association. 2012.
30. Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012;2(1):e53.
31. Huang JJ, Yu J, Li JY, Liu YT, Zhong RQ. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol. 2012;29(4):2402-8.
32. Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 2012;37(11):460-5.
33. Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, Watanabe Y, et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One. 2010;5(10):e13247.
34. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115(12):931-5.
35. Littlewood T, Mandelli F. The effects of anemia in hematologic malignancies: more than a symptom. Semin Oncol. 2002;29(3 Suppl 8):40-4.
36. Kim JE, Yoo C, Lee DH, Kim SW, Lee JS, Suh C. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol. 2010;89(4):391-7.
37. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell. 2007;12(3):252-65.
38. Gallo A, Tandon M., Alevizos I, Illei G. The majority of microRNAs derectable in serum and saliva is concentrated in exosomes. PlosOne. 2012;7(3):e30679
39. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, et al. High-resolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9(4):313-25.
40. Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008;112(10):4235-46.
41. Nemec P, Zemanova Z, Greslikova H, Michalova K, Filkova H, Tajtlova J, et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant. 2010; 16(4):548-54.
42. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101(4):1520-9.
43. Tichý M, Maisnar V, Palicka V, Friedecký B, Vávrová J, Novotná H, et al. International Staging System required standardization of biochemical laboratory testing in multiple myeloma. Neoplasma. 2006;53(6):492-4.